- Home
- CHRS vs KNDI Comparison
CHRS vs KNDI Comparison
Compare CHRS & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KNDI
- Stock Information
- Founded
- CHRS 2010
- KNDI 2002
- Country
- CHRS United States
- KNDI China
- Employees
- CHRS N/A
- KNDI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KNDI Auto Manufacturing
- Sector
- CHRS Health Care
- KNDI Consumer Discretionary
- Exchange
- CHRS Nasdaq
- KNDI Nasdaq
- Market Cap
- CHRS 84.2M
- KNDI 96.3M
- IPO Year
- CHRS 2014
- KNDI N/A
- Fundamental
- Price
- CHRS $0.76
- KNDI $1.09
- Analyst Decision
- CHRS Buy
- KNDI
- Analyst Count
- CHRS 3
- KNDI 0
- Target Price
- CHRS $4.68
- KNDI N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- KNDI 93.5K
- Earning Date
- CHRS 08-07-2025
- KNDI 08-15-2025
- Dividend Yield
- CHRS N/A
- KNDI N/A
- EPS Growth
- CHRS N/A
- KNDI N/A
- EPS
- CHRS N/A
- KNDI N/A
- Revenue
- CHRS $272,251,000.00
- KNDI $127,569,613.00
- Revenue This Year
- CHRS N/A
- KNDI N/A
- Revenue Next Year
- CHRS $106.56
- KNDI N/A
- P/E Ratio
- CHRS N/A
- KNDI N/A
- Revenue Growth
- CHRS 19.87
- KNDI 3.21
- 52 Week Low
- CHRS $0.66
- KNDI $0.89
- 52 Week High
- CHRS $2.43
- KNDI $2.24
- Technical
- Relative Strength Index (RSI)
- CHRS 46.54
- KNDI 45.75
- Support Level
- CHRS $0.72
- KNDI $1.06
- Resistance Level
- CHRS $0.77
- KNDI $1.16
- Average True Range (ATR)
- CHRS 0.04
- KNDI 0.07
- MACD
- CHRS 0.00
- KNDI 0.00
- Stochastic Oscillator
- CHRS 51.92
- KNDI 29.13
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.